BARI 2D TRIAL
BARI 2D TRIAL
BARI 2D TRIAL
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>BARI</strong> <strong>2D</strong> <strong>TRIAL</strong><br />
SAMIR WAFA, MD<br />
PROFESSOR OF CARDIOLOGY<br />
AIN SHAMS UNIVERSITY
<strong>BARI</strong> <strong>2D</strong> Trial<br />
Randomized controlled trial that tested 2 treatment<br />
strategies in a 2 x 2 factorial design among patients in<br />
whom angina symptoms were controlled (82%) or<br />
asymptomatic (18%)<br />
Comparison of prompt coronary revascularization and<br />
intensive medical therapy, with intensive medical<br />
therapy alone with later revascularization only for<br />
clinical indications<br />
Choice of the intended PCI or CABG procedure was selected by<br />
the treating physicians before randomization<br />
Comparison of an insulin sensitizing strategy to an<br />
insulin provision strategy for glycemic management<br />
with target HbA1c of < 7.0%
<strong>BARI</strong> <strong>2D</strong> Trial: Study Design<br />
2368 patients with mild to moderate CAD and Type 2 diabetes prior to<br />
randomization. Prospective. Randomized. Mean follow-up 5.3 years<br />
R<br />
CABG Stratum (N= 763)<br />
R<br />
OMT alone<br />
CABG +OMT<br />
(N= 385)<br />
(N= 378)<br />
R<br />
R<br />
PCI Stratum (N= 1605)<br />
R<br />
OMT alone<br />
PCI +OMT<br />
(N= 807)<br />
(N= 798)<br />
R<br />
R<br />
Provision<br />
(N= 194)<br />
Sensitization<br />
(N= 191)<br />
Provision<br />
(N= 190)<br />
Sensitization<br />
(N= 188)<br />
Provision<br />
(N= 399)<br />
Sensitization<br />
(N= 408)<br />
Provision<br />
(N= (N= 402) 402)<br />
Sensitization<br />
(N= 396)<br />
<br />
<br />
Primary Endpoint: Death (from any cause)<br />
Secondary Endpoint: Composite of Death, MI, or Stroke<br />
Copyleft Clinical Trial Results. You Must Redistribute Slides<br />
<strong>BARI</strong> <strong>2D</strong> Study Group, NEJM 2009
Change language